Repository logo
 

RECQL5 Suppresses Oncogenic JAK2-Induced Replication Stress and Genomic Instability.


Type

Article

Change log

Authors

Chen, Edwin 
Ahn, Jong Sook 
Sykes, David B 
Breyfogle, Lawrence J 
Godfrey, Anna L 

Abstract

JAK2V617F is the most common oncogenic lesion in patients with myeloproliferative neoplasms (MPNs). Despite the ability of JAK2V617F to instigate DNA damage in vitro, MPNs are nevertheless characterized by genomic stability. In this study, we address this paradox by identifying the DNA helicase RECQL5 as a suppressor of genomic instability in MPNs. We report increased RECQL5 expression in JAK2V617F-expressing cells and demonstrate that RECQL5 is required to counteract JAK2V617F-induced replication stress. Moreover, RECQL5 depletion sensitizes JAK2V617F mutant cells to hydroxyurea (HU), a pharmacological inducer of replication stress and the most common treatment for MPNs. Using single-fiber chromosome combing, we show that RECQL5 depletion in JAK2V617F mutant cells impairs replication dynamics following HU treatment, resulting in increased double-stranded breaks and apoptosis. Cumulatively, these findings identify RECQL5 as a critical regulator of genome stability in MPNs and demonstrate that replication stress-associated cytotoxicity can be amplified specifically in JAK2V617F mutant cells through RECQL5-targeted synthetic lethality.

Description

Keywords

Animals, Apoptosis, Cell Line, Tumor, Cell Survival, DNA Breaks, Double-Stranded, DNA Replication, Furans, Gene Knock-In Techniques, Genomic Instability, Humans, Hydroxyurea, Janus Kinase 2, Mice, Mice, Inbred C57BL, Mutagenesis, Site-Directed, Neoplasms, Phosphatidylinositol 3-Kinases, Phosphoinositide-3 Kinase Inhibitors, Pyridines, Pyrimidines, RNA Interference, RNA, Small Interfering, RecQ Helicases, Signal Transduction

Journal Title

Cell Rep

Conference Name

Journal ISSN

2211-1247
2211-1247

Volume Title

13

Publisher

Elsevier BV
Sponsorship
Wellcome Trust (104710/Z/14/Z)
Leukaemia & Lymphoma Research (13003)
Blood Cancer UK (07037)
Wellcome Trust (097922/Z/11/B)
Cancer Research Uk (None)
This work was supported by the NIH (K08 HL109734 to AM) and the MPN Research Foundation (AM). A.M. receives support from the Jeanne D. Housman Fund for Research on Myeloproliferative Disorders and is a recipient of a Damon Runyon clinical investigator award. EC is a recipient of a Lady Tata Memorial Trust Award.